Cellectis

Yahoo Finance • last month

European Equities Traded in the US as American Depositary Receipts Track Higher in Tuesday Trading

European equities traded in the US as American depositary receipts were tracking higher late Tuesday PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 2 months ago

Monthly information on share capital and company voting rights

(Article 223-16 of General Regulation of the French financial markets authority) NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of shares in the capitalTotal numb... Full story

Yahoo Finance • 2 months ago

Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social

(Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) NEW YORK, 07 août 2025 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Growth Code ISIN : FR0010425595 DateNombre total d’actions composant le capital social... Full story

Yahoo Finance • 2 months ago

Cellectis GAAP EPS of -$0.24 misses by $0.03, revenue of $16M beats by $4.36M

* Cellectis press release [https://seekingalpha.com/pr/20188243-cellectis-reports-second-quarter-2025-financial-results-and-business-updates] (NASDAQ:CLLS [https://seekingalpha.com/symbol/CLLS]): Q2 GAAP EPS of -$0.24 misses by $0.03.... Full story

Yahoo Finance • 2 months ago

Cellectis Reports Second Quarter 2025 Financial Results & Business Updates

Cellectis Inc. Cellectis to host an Investor R&D Day in New York City on October 16, 2025: Phase 1 dataset and late-stage development strategy for lasme-cel (UCART22) in r/r B-ALL to be presented End-of-Phase 1 meetings with FDA & EMA fo... Full story

Yahoo Finance • 2 months ago

Cellectis to Report Second Quarter 2025 Financial Results on August 4, 2025

NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapie... Full story

Yahoo Finance • 2 months ago

Cellectis publiera ses résultats financiers du deuxième trimestre 2025 le 4 août 2025

NEW YORK, 28 juill. 2025 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS) (la « Société »), société de biotechnologie de stade clinique, qui utilise sa technologie pionnière d'édition de génome TALEN® pour développer... Full story

Yahoo Finance • 2 months ago

Unlocking Oncology’s Future: 3 Trending Cancer Biotech Stocks with ‘Strong Buy’ Ratings

Syringe and red cross by Stadratte via iStock Cancer remains one of the most relentless challenges in modern medicine. In 2025, over 2 million new cancer cases are expected to be diagnosed in the United States. More than 618,000 people wi... Full story

Yahoo Finance • 5 months ago

Cellectis SA (CLLS) Q4 2024 Earnings Call Highlights: Strategic Collaborations and Financial ...

Equity Investment: AstraZeneca completed an additional equity investment of $140 million in Cellectis. Cash and Cash Equivalents: $264 million as of December 31, 2024, compared to $156 million as of December 31, 2023. Revenue from Collabor... Full story

Yahoo Finance • 8 months ago

Totus Medicines Appoints Simon Harnest, MSc, BSc, as Chief Financial Officer

EMERYVILLE, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Totus Medicines, a company revolutionizing small molecule drug discovery and development using covalent DNA-encoded libraries and AI tools, today announced the appointment of Simon Ha... Full story

Yahoo Finance • 3 years ago

Cellectis Announces Closing of Global Offering and Exercise of Underwriters’ Option to Purchase Additional Shares

NEW YORK, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Cellectis S.A. (“Cellectis” or the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving c... Full story

Yahoo Finance • 3 years ago

Cellectis to Report Second Quarter 2022 Financial Results

Cellectis Inc. NEW YORK, July 28, 2022 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies... Full story

Yahoo Finance • 3 years ago

Cellectis S.A. Reports Results from Annual Shareholders’ General Meeting Held on June 28, 2022

Cellectis Inc. NEW YORK, June 28, 2022 (GLOBE NEWSWIRE) -- Cellectis S.A. held its Annual Shareholders’ General Meeting (Euronext Growth: ALCLS – Nasdaq: CLLS) on June 28, 2022 at its head office in Paris, France. At the meeting, during... Full story

Yahoo Finance • 3 years ago

Why Cellectis' Shares Rose 22.7% This Week

Shares of Cellectics (NASDAQ: CLLS), a clinical-stage biopharmaceutical company that specializes in oncology, rose 22.7% this week, according to data from S&P Global Market Intelligence. The company released research data on its new univer... Full story

Yahoo Finance • 3 years ago

Cellectis Publishes Two Articles in Nature Communications Providing Strong Preclinical Validation of UCART123 to Treat AML and BPDCN

Preclinical data demonstrates that UCART123 effectively eliminates AML with no major impact on normal hematopoietic progenitor cellsPreclinical data shows proof-of-principle that UCART123 cells have potent anti-BPDCN activityHuman evaluati... Full story

Yahoo Finance • 3 years ago

Cellectis publie deux articles dans Nature Communications démontrant une validation préclinique solide du produit candidat UCART123 pour traiter la LAM et le TCPDB

Les données précliniques démontrent que le produit candidat UCART123 élimine efficacement la leucémie myéloblastique aigüe (LAM) sans impact majeur sur les cellules progénitrices hématopoïétiques Les données précliniques démontrent que les... Full story